Sideline Gold on Fe...
Health Care: Drugs
AstraZeneca PLC (AZN: NYSE)
$50.98 0.01 | 0.02%
06/18/13 - 04:01 PM ET
1.20K / 1.98M
Vol / Avg. Vol:50.73 / 50.97
Open / Prev. Close:50.73 - 51.06
Today's Range:42.68 - 53.45
52 Wk Range:7.85%
Performance YTD:TheStreet Rating:
Portfolios with AZN
- Portfolio NameUser Type
- ProRenaissance Technologies
- UserDC
- ContributorRocket Stocks for the Week ...
- ContributorRocket Stocks for the Week ...
- Contributor7 Big-Pharma Stocks With Un...
- UserCurrent
- Contributor9 High-Yield Stocks to Cons...
- UserGFNN Stockdiagnostics 14
- UserThe Coming M&A boom
- ContributorHighest-Yielding Drug Stocks
Latest AZN Headlines from TheStreet
- 4 Buy-Rated Dividend Stocks 04.19.13 | 11:04 am
- AstraZeneca Stock Hits New 52-Week High (AZN) 04.09.13 | 11:04 am
- Astra, Rigel Arthritis Pill Posts Mixed Trial Results 04.05.13 | 05:04 am
- Cramer's 6 Stocks in 60 Seconds: YELP NAT AZN HBI TXN URBN (Update 1) 04.02.13 | 05:04 pm
- Stocks to Watch: Nasdaq OMX, Goldman, Ford, GM 04.02.13 | 05:04 am
- AstraZeneca Stock Hits New 52-Week High (AZN) 04.01.13 | 10:04 am
- 4 Stocks Going Ex-Dividend Tomorrow: VNR, VMI, INGR, AZN 03.26.13 | 10:03 am
- AstraZeneca Stock To Go Ex-dividend Tomorrow (AZN) 03.26.13 | 09:03 am
- AstraZeneca Rises On Unusually High Volume (AZN) 03.21.13 | 01:03 pm
- 3 Stocks Boosting The Health Care Sector Higher 03.21.13 | 01:03 pm
Press Releases for AZN
- AstraZeneca And Bristol-Myers Squibb Announce Top Line Results For SAVOR-TIMI-53 Cardiovascular Outcomes Trial Of Onglyza® (saxagliptin) - Business Wire 06.19.13 | 02:06 am
- AstraZeneca And Bristol-Myers Squibb To Present New Data At American Diabetes Association 73rd Scientific Sessions® - Business Wire 06.14.13 | 09:06 am
- OMTHERA PHARMACEUTICALS SHAREHOLDER ALERT: Levi & Korsinsky Announces Investigation Into Possible Breaches Of Fiduciary Duty By Board Of Omthera Pharmaceuticals, Inc. In Connection With Sale Of Company To AstraZeneca Plc - PR Newswire 05.30.13 | 04:05 pm
- AstraZeneca To Establish Strategic R&D Center In Gaithersburg, Md; Wilmington Remains North America Commercial Headquarters - Business Wire 03.18.13 | 09:03 am
- AstraZeneca Encourages Atherosclerosis Education Among High Risk Patients During American Heart Month - PR Newswire 02.14.13 | 09:02 am
- AstraZeneca Recognized As A Top Company For Female Executives - Business Wire 02.05.13 | 12:02 pm
- AstraZeneca HealthCare Foundation: Connections For Cardiovascular HealthSM Accepting Grant Applications - Business Wire 01.09.13 | 09:01 am
- BRILINTA (Ticagrelor) Receives Additional Class I Recommendation In Updated ACCF/AHA Guidelines For The Management Of STEMI Patients - Business Wire 12.17.12 | 03:12 pm
- CRESTOR® US Patent Upheld By Court Of Appeals For The Federal Circuit - Business Wire 12.14.12 | 01:12 pm
- AstraZeneca Updates US Label For FASLODEX® (fulvestrant) Injection - Business Wire 12.05.12 | 11:12 am
Partner Headlines for AZN
- Astrazeneca, Bristol-Myers Squibb Release Statement to American Diabetes Association - Benzinga 06.12.13 | 01:06 pm
- Dynavax Down on Heplisav Delay - Analyst Blog - Zacks 06.12.13 | 12:06 am
- Futures Whittle Early Gains; AstraZeneca To Acquire Pearl - Investor's Business Daily 06.10.13 | 08:06 am
- AstraZeneca Presents Olaparib Data - Analyst Blog - Zacks 06.04.13 | 12:06 am
- U.S. Steel, Genomic Health and Other Stocks Insiders Are Buying - Benzinga 05.18.13 | 03:05 pm
- Medicines Co. Earnings Top Views; New Drugs Await - Investor's Business Daily 04.24.13 | 04:04 pm
- Astrazeneca Earnings Preview: Can This Streak Continue? - Wall St. Cheat Sheet 04.23.13 | 02:04 am
- Biotech Alkermes Poised To Swell On Pipeline Wins - Investor's Business Daily 04.16.13 | 05:04 pm
- European Stocks Weaken on Downbeat U.S. Jobs Data, North Korean Worries - NASDAQ 04.05.13 | 04:04 pm
- Will AstraZeneca’s Patent Setback Put Off These Top Institutional Shareholders? - Wall St. Cheat Sheet 04.02.13 | 12:04 pm
